Gemvax & Kael

This study looked at the long-term safety of a drug called GV1001 in people with progressive supranuclear palsy (PSP), a rare brain disorder that affects movement and balance. Researchers followed 67 patients who had already completed a previous GV1001 study for an additional 12 …

This study tested an experimental drug called GV1001 in 199 people with mild to moderate Alzheimer's disease. Participants received either a low or high dose of the drug or a placebo as injections under the skin for 52 weeks. The goal was to see if GV1001 could slow down memory a…

This study tested a drug called GV1001 in 78 people with Progressive Supranuclear Palsy (PSP), a rare brain disease that affects movement and thinking. Participants received daily injections of either a low dose, a high dose, or a placebo for 6 months. The goal was to see if the …

This early-stage trial tested the safety of a drug called GV1001 in 59 healthy adults. Participants received either a single dose or multiple doses of the drug or a placebo. The goal was to check for side effects and how the drug moves through the body, not to treat any disease. …